
Sign up to save your podcasts
Or
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD.
Related Content:
4.9
1212 ratings
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD.
Related Content:
129 Listeners
288 Listeners
315 Listeners
162 Listeners
98 Listeners
36 Listeners
485 Listeners
270 Listeners
9 Listeners
17 Listeners
18 Listeners
23 Listeners
83 Listeners
1,090 Listeners
1,320 Listeners
29 Listeners
184 Listeners
507 Listeners
321 Listeners
19 Listeners
360 Listeners
98 Listeners